Reelin Therapeutics, Inc

Our team has shown in multiple sclerosis and atherosclerosis that the reduction of plasma Reelin restores endothelial integrity, thereby decreasing inflammation and disease burden. To develop this approach, we (Drs. Calvier, Herz, and Kounnas) cofounded Reelin Therapeutics to develop primarily anti-Reelin therapies for patients with chronic inflammatory diseases. Additionally, we aim to create a specific Reelin ELISA suitable for clinical use. Therefore, advances in knowledge in our l will be translated toward clinical applications through a partnership between UT Southwestern and Reelin Therapeutics.